Unknown

Dataset Information

Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.


ABSTRACT:

Background and aims

Treatment of de novo malignancies and recurrent hepatocellular carcinoma with immune checkpoint inhibitors (ICI) in liver transplant recipients (LT) is an attractive strategy that is infrequently pursued because of the lack of strong evidence regarding their safety and efficacy. In this systematic review with pooled analysis, we aimed to assess safety and efficacy of ICI therapy following LT.

Methods

We performed a systematic search of case reports and series published until January 2022. We included 31 publications reporting a total of 52 patients treated with ICIs after LT and assessed in a pooled analysis the risk of graft rejection and the outcome of ICI therapy.

Results

Acute graft rejection occurred in 15 patients (28.8%) and 7 patients (13.4

SUBMITTER: Kayali S 

PROVIDER: S-EPMC10087158 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature